ORNIPURAL Stimulation of hepato-digestive activity in case of digestive disorders and hepatic impairment.complete injectable solution combining hepatoprotective, lipotropic and diuretic active ingredients (betaine, sorbitol, ornithine, citrulline and arginine).50 to 100 ml in adult cattle (I.M., S.C. or slow I.V. administration).

Description

Properties PHARMACODYNAMIC PROPERTIES Marbofloxacin is a bactericidal anti-infectious synthesis belonging to the fluoroquinolones group. It acts by inhibition of DNA-gyrase. Its very broad spectrum is directed towards Gram positive (especially Staphylococcus and Streptococcus), Gram negative bacteria (Escherichia Coli, Salmonella Aertricke, Citrobacter freundii, Aerobacter cloacae, Serratia marcescens, Morganella morganii, Proteus sp, Klebsiella sp, Shigella sp, Pasteurella sp, Haemophilus sp, Moraxella sp, Pseudomonas sp, Brucella canis) and Mycoplasma. PHARMACOKINETIC PARTICULARS After oral use at the recommended dose of 2 mg/kg in the cat and dog, Marbofloxacin is rapidly absorbed and reaches maximal plasmatic concentrations of 1.5 µg/ml in 2 hours approximately. The bioavailability of Marbofloxacin is close to 100 %. It is slightly related to plasmatic proteins (< than 10 %) and is widely distributed in the entire organism. In the majority of tissues (liver, kidney, skin, lungs, bladder and digestive tract), tissular concentrations are higher than those of plasma. Marbofloxacin is slowly eliminated (half-life of elimination : 14 hours in the dog and 10 hours in the cat) and mainly in active form in the urines (2/3) and faeces (1/3). Contra-indication Marbofloxacin is well tolerated in growing medium sized-dogs until doses reaching 4 mg/kg/day for 13 weeks. However, it is not recommended to use it in giant breeds dogs under 1 year. Side effects Minor side effects may occur during treatment, such as vomiting, softening of saddles, alteration of the thirst, transitory hyperactivity. These signs disappear spontaneously and it is not necessary to stop treatment. Use during pregnancy and  Studies in animals of laboratory (rat, rabbit) have not produced any evidence of a teratogenic, foetotoxic or maternotoxic effect of Marbofloxacin at the dose used in therapeutics. Harmlessness of the product in queens during pregnancy and suckling has not been shown. The use of this product in pregnant or suckling females should be avoided or only accordingly to the benefit/risk assessment by the responsible veterinarian. Interaction In the case of concomitant oral administration of cations (aluminium, calcium, iron, magnesium), the bioavailability of Marbofloxacin can be reduced. It is recommended to lower the dose of Theophylline in the case of concomitant administration. Composition:

• Ornipural Solution 100ml for Animals.
• Contains:
• Betaine…………………………….…15.0mg.
• Arginine (as hydrochloride)…….33.3mg.
• Ornithin (as hydrochloride)……..11.8mg.
• Citrulline………………………………10.0mg.
• Sorbitol………………………………200.0mg.
• Metacresol……………………………..3.0mg.
• Excipient QS……………………………1.0ml.
• ———————–

  Indications:

• Camel, Cattle, Dogs, Cats, Horse And Sheep.
• Stimulation Of The Hepatodigestive Activity In Digestive Disorders And Kidney Failure.
• Not for Human Consumption.
• Expiry Date is printed on the inside bottle.
• Imported from FRance.

   Dosage And Administration:    By Intramuscular Or Slow Intravenous Administration:

• In Adult Cattle And Horse: 50 to 100ml.
• In Calves And Foals: 1ml For 5 to 10kg Of Body Weight.
• In Adult Sheep: 10 to 15ml.
• In Lamb: 3 to 5ml.
• In Dogs And Cats: 2 to 5ml Depending On The Body Weight.
• Renew Injection 4 to 5 Times Within An Interval Of 2 Days.

  Withdrawal Period:

• For Meat/Cattle,Sheep: Zero Days.
• For Milk: Zero Days.